Skip to main content

Table 5 Anti-fibrotic discontinuation, by medication and reason

From: Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

Discontinuation Reason

Pirfenidone (n = 391)

Nintedanib (n = 312)

Cost

0

1

Side effects

34

25

Patient preference

2

1

Physician preference

6

6

Total

42

33

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us